4 Buy-Rated Growth Stocks to Snatch-up in May
- ByStockNews-
Even though growth stocks fell out of favor this year with investors who chose to rotate to cyclical stocks to capitalize on the economic recovery, some are still solid bets...
Even though growth stocks fell out of favor this year with investors who chose to rotate to cyclical stocks to capitalize on the economic recovery, some are still solid bets...
Key Takeaways Health Care Select Sector SPDR ETF (XLV) earns a five-star rating from CFRA for its high reward potential, modest risks, and low costs relative to sector equity ETF...
(Reuters) -Thermo Fisher Scientific Inc beat first-quarter profit estimates on Thursday boosted by revenue at its life sciences unit, which makes raw materials used in COVID-19...
Other than earnings, we’ve had almost no numbers to crunch so far this week. That changes starting today.Weekly crude inventories come out today, followed by initial jobless...
After four weeks of gains, what can Wall Street do for an encore? We’re about to find out as the earnings parade continues.Despite nice results this morning from Coca-Cola...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Buy | Buy |
| Technical Indicators | Strong Sell | Sell | Strong Buy | Strong Sell | Strong Buy |
| Summary | Strong Sell | Sell | Neutral | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 315.94 | 316.85 | 309.08 | +10.68 | +3.50% | 19.25M | NASDAQ | |||
| 2,278.38 | 2,284.72 | 2,250.00 | +49.34 | +2.21% | 1.60M | NASDAQ | |||
| 14.96 | 15.02 | 14.93 | +0.09 | +0.57% | 728.75K | NASDAQ | |||
| 71.87 | 72.22 | 67.02 | +5.50 | +8.29% | 7.20M | NASDAQ | |||
| 116.52 | 119.36 | 116.41 | -2.50 | -2.10% | 2.47M | NYSE | |||
| 66.54 | 68.60 | 66.50 | -1.15 | -1.70% | 2.99M | NYSE | |||
| 21.24 | 21.34 | 20.87 | -0.42 | -1.94% | 1.82M | NYSE | |||
| 42.13 | 42.22 | 41.81 | +0.43 | +1.03% | 1.21M | OTC Markets | |||
| 3.56 | 3.65 | 3.43 | +0.38 | +11.95% | 1.38M | NASDAQ | |||
| 2,316.16 | 2,321.14 | 2,283.32 | +54.19 | +2.40% | 1.33M | NASDAQ | |||
| 42.17 | 43.09 | 41.22 | +1.27 | +3.11% | 2.30M | NASDAQ | |||
| 88.96 | 89.27 | 88.78 | +0.56 | +0.63% | 1.77M | NYSE | |||
| 209.51 | 210.94 | 206.02 | +3.43 | +1.66% | 31.63M | NYSE | |||
| 18.29 | 18.92 | 17.37 | +0.95 | +5.48% | 1.88M | NASDAQ | |||
| 384.00 | 386.71 | 380.63 | +5.89 | +1.56% | 1.14M | NYSE |
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Company focuses on cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicine. It offers products, including FreeStyle, PediaSure, Pedialyte, Similac, EleCare, ZonePerfect, Juven, Ensure and Glucerna. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. The cardiovascular's products include Portico, MitraClip, Dilatation Catheter, among others. The diagnostics products include IntelliFISH, Vysis ALK, STARLIMS, PathVysion, AlinIQ, among others.